Drug Trials Snapshots: ROZLYTREK

19:12 EDT 12 Sep 2019 | FDA

ROZLYTREK is a drug used to treat adult patients with a type of non-small cell lung cancer (NSCLC) which is caused by an abnormal ROS1 gene and, has spread to other parts of the body (metastatic)

Original Article: Drug Trials Snapshots: ROZLYTREK


More From BioPortfolio on "Drug Trials Snapshots: ROZLYTREK"

Quick Search

Relevant Topics

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...